Intervention Review

You have free access to this content

Amantadine and rimantadine for influenza A in adults

  1. Tom Jefferson1,*,
  2. Vittorio Demicheli2,
  3. Carlo Di Pietrantonj2,
  4. Daniela Rivetti3

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 19 APR 2006

Assessed as up-to-date: 26 APR 2008

DOI: 10.1002/14651858.CD001169.pub3


How to Cite

Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD001169. DOI: 10.1002/14651858.CD001169.pub3.

Author Information

  1. 1

    The Cochrane Collaboration, Roma, Italy

  2. 2

    Azienda Sanitaria Locale ASL AL, Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field, Alessandria, Piemonte, Italy

  3. 3

    Servizio di Igiene e Sanita' Pubblica, ASL 19 Asti, Public Health Department, Asti, Italy

*Tom Jefferson, The Cochrane Collaboration, Via Puglie 23, Roma, 00187, Italy. jefferson.tom@gmail.com. jefferson@assr.it.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 19 APR 2006

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Oral amantadine versus placebo (prophylaxis), Outcome 1 Influenza cases.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Oral amantadine versus placebo (prophylaxis), Outcome 2 ILI cases.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Oral amantadine versus placebo (prophylaxis), Outcome 3 Adverse effects.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Oral amantadine versus placebo (prophylaxis), Outcome 4 Viral nasal shedding or persistence in upper airways at 2 to 5 days.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Oral amantadine versus placebo (prophylaxis), Outcome 5 Influenza cases (asymptomatic).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Oral rimantadine versus placebo (prophylaxis), Outcome 1 Influenza cases.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Oral rimantadine versus placebo (prophylaxis), Outcome 2 ILI cases.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Oral rimantadine versus placebo (prophylaxis), Outcome 3 Adverse effects.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Oral rimantadine versus placebo (prophylaxis), Outcome 4 Influenza cases (asymptomatic).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Oral amantadine versus oral rimantadine (prophylaxis), Outcome 1 Influenza cases.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Oral amantadine versus oral rimantadine (prophylaxis), Outcome 2 ILI cases.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Oral amantadine versus oral rimantadine (prophylaxis), Outcome 3 Adverse effects.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Oral amantadine versus placebo (treatment), Outcome 1 Duration of fever (37 degrees centigrade or more) in days.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Oral amantadine versus placebo (treatment), Outcome 2 Cases with fever at 48 hours.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Oral amantadine versus placebo (treatment), Outcome 3 Adverse effects.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Oral amantadine versus placebo (treatment), Outcome 4 Duration of hospital stay (in days).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Oral amantadine versus placebo (treatment), Outcome 5 Viral nasal shedding or persistence in upper airways at 2 to 5 days.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Oral rimantadine versus placebo (treatment), Outcome 1 Duration of fever (37 degrees centigrade or more) in days.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Oral rimantadine versus placebo (treatment), Outcome 2 Cases with fever at 48 hours.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Oral rimantadine versus placebo (treatment), Outcome 3 Adverse effects.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Oral rimantadine versus placebo (treatment), Outcome 4 Viral nasal shedding or persistence in upper airways at 2 to 5 days.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Oral amantadine versus oral rimantadine (treatment), Outcome 1 Duration of fever (37 degrees centigrade or more) in days.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Oral amantadine versus oral rimantadine (treatment), Outcome 2 Cases with fever at 48 hours.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Oral amantadine versus oral rimantadine (treatment), Outcome 3 Adverse effects.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Oral or inhaled amantadine versus placebo or aspirin, Outcome 1 Viral nasal shedding or persistence in upper airways at 2 to 5 days.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Oral amantadine versus standard medication (treatment), Outcome 1 Duration of fever (37 degrees centigrade or more) in days.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Oral amantadine versus standard medication (treatment), Outcome 2 Adverse effect - insomnia.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Oral amantadine versus standard medication (treatment), Outcome 3 Viral nasal shedding or persistence in upper airways at 2 to 5 days.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Inhaled amantadine versus placebo (treatment), Outcome 1 Symptoms score in confirmed cases (respiratory illness).
[Analysis 9.2]
Analysis 9.2. Comparison 9 Inhaled amantadine versus placebo (treatment), Outcome 2 Symptoms score in confirmed cases (constitutional illness).
[Analysis 9.3]
Analysis 9.3. Comparison 9 Inhaled amantadine versus placebo (treatment), Outcome 3 Adverse effects - local - nasal irritation.
[Analysis 9.4]
Analysis 9.4. Comparison 9 Inhaled amantadine versus placebo (treatment), Outcome 4 Viral nasal shedding or persistence in upper airways at 2 to 5 days.